These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8591979)

  • 1. Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity.
    Rothman RB
    J Clin Psychiatry; 1996 Feb; 57(2):92-3. PubMed ID: 8591979
    [No Abstract]   [Full Text] [Related]  

  • 2. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
    Khan M; Lum CT; Rao V
    Transplant Proc; 1995 Feb; 27(1):975-6. PubMed ID: 7879251
    [No Abstract]   [Full Text] [Related]  

  • 4. New agent for obesity management.
    Clemenson ND
    J Fam Pract; 1996 Sep; 43(3):224; author reply 225. PubMed ID: 8797741
    [No Abstract]   [Full Text] [Related]  

  • 5. Appetite suppressants for obesity.
    Budenholzer B
    J Fam Pract; 1997 Jan; 44(1):19-20. PubMed ID: 9010359
    [No Abstract]   [Full Text] [Related]  

  • 6. [Research and experience with fenfluramine in obesity].
    Pawan GS
    Vie Med Can Fr; 1973 May; 2(5):415-22. PubMed ID: 4732200
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats.
    Halladay AK; Fisher H; Wagner GC
    Alcohol; 2000 Jan; 20(1):19-29. PubMed ID: 10680713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical treatment of obesity.
    Blackburn GL; Miller D; Chan S
    Nurs Clin North Am; 1997 Dec; 32(4):831-48. PubMed ID: 9386228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of obesity. A call for prudence and professionalism.
    Kushner R
    Arch Intern Med; 1997 Mar; 157(6):602-4. PubMed ID: 9080914
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacologic management of obesity.
    Cerda JJ
    J Fla Med Assoc; 1997 Feb; 84(2):89-92. PubMed ID: 9066231
    [No Abstract]   [Full Text] [Related]  

  • 13. Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
    Katz DA; Maloney MJ; Sutkamp JC; McConville BJ
    Int J Eat Disord; 1999 May; 25(4):469-74. PubMed ID: 10202659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine (Prozac) and other drugs for treatment of obesity.
    Med Lett Drugs Ther; 1994 Nov; 36(936):107-8. PubMed ID: 7968782
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of phentermine plus fenfluramine: neurochemical and neurotoxic effects.
    Halladay AK; Fisher H; Wagner GC
    Neurotoxicology; 1998 Apr; 19(2):177-83. PubMed ID: 9553954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between health-related quality of life and weight loss.
    Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S
    Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminorex to fen/phen: an epidemic foretold.
    Fishman AP
    Circulation; 1999 Jan 5-12; 99(1):156-61. PubMed ID: 9884392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.